Product Images Gazyva

This is a statistical report on the median time of two treatments for some unknown medical condition. The first treatment is a drug called Bendamustine, and it was administered to 166 patients while the other treatment is GAZYVA plus bendamustine, given to 155 patients. The data suggests that the combination treatment of GAZYVA plus bendamustine outperformed the Bendamustine in terms of patient survival rate as the p-value is less than 0.0001. Unfortunately, further details of the medical condition and treatments are not available from the text provided.*

This is a graph that shows the probability of S, stratified by Modian time in months. The y-axis shows stratified HR o values. The x-axis shows the time frame in months, ranging from 0 to 102 months. Two different treatments are compared: Bendamustine and GAZYVA plus bendamustine. The Bendamustine treatment group included 171 patients, and the GAZYVA plus bendamustine group included 164 patients. The graph also displays the Logrankpvalus, which equals 0.00343. Finally, this graph shows the number of patients at risk over the same period.*

This appears to be a table or graph with data related to two treatment groups, one receiving binutuzumab plus chemotherapy (referred to as G-chemo) and the other receiving ruximab plus chemotherapy (referred to as R-chemo). The data includes information on the number of patients in each group, the length of treatment (in months), and the progression-free survival (PFS) rates. The PFS rate for the G-chemo group is shown to be significantly higher than the rate for the R-chemo group, with a hazard ratio of 0.72 and a confidence interval of 0.56-0.83.*

Gazyva® is an injectable medication used for Intravenous Infusion After Dilution. It comes in a Single-Dose Vial containing 1000 mg/40 mL (25 mg/mL) of obinutuzumab. It is important to discard any unused portion of the medication as it has no preservatives. The medication can be obtained from Genentech and is identified by the NDC code 50242-070-01.*